In vitro activity of AR-709 against Streptococcus pneumoniae.
We investigated the in vitro activity of AR-709, a novel diaminopyrimidine antibiotic currently in development for treatment of community-acquired upper and lower respiratory tract infections, against 151 Streptococcus pneumoniae strains from various European countries. AR-709 showed excellent activity against both drug-susceptible and multidrug-resistant pneumococci.
Jansen
W T M
WT
University Medical Center Utrecht, Medical Microbiology Dept., G 04.614, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. w.t.m.jansen@umcutrecht.nl
Verel
A
A
Verhoef
J
J
Milatovic
D
D
D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology*; D017714:Community-Acquired Infections / Q000382:microbiology; D024901:Drug Resistance, Multiple, Bacterial; D005060:Europe; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods; D011743:Pyrimidines / Q000737:chemistry / Q000494:pharmacology*; D012141:Respiratory Tract Infections / Q000382:microbiology; D013296:Streptococcus pneumoniae / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D011743:Pyrimidines